Pick · 4.0% · large · Health Care · last 121.51
Entry 107.00–114.00 · Stop 99.00 · Target 140.00 · Buy ≈ 17 shares (≈ $2,066 at 121.51)
Thesis (long, position, conviction 60)
Bull: Halozyme's royalty-driven model is compounding fast: Q2 2026 revenue rose 47.6% YoY to $481.0M with royalty revenue up 50% to $308M (F-HALO-1, F-HALO-2), and operating income (+42%) and net income (+39%) both grew faster than revenue, showing operating leverage (F-HALO-3, F-HALO-4). Management raised FY2026 guidance across the board on Aug 6 — revenue to $1.835–1.910B, adjusted EBITDA to $1.225–1.280B, non-GAAP EPS to $8.65–9.00 (F-HALO-5) — implying the stock trades around 13-14x the midpoint of forward non-GAAP EPS, which is inexpensive for a business growing revenue near 50% with expanding margins. Business development is ahead of plan: five ENHANZE/Hypercon deals signed YTD versus a stated goal of three (F-HALO-7), which extends the royalty annuity runway. Capital allocation is shareholder-friendly ($332.8M of buybacks in Q2 at $69.30/share, F-HALO-6), and the company termed out financing with $1.5B of low-coupon (1.50%) 2033 converts at a conversion price of $139.84 — ~15% above the current price — giving balance-sheet flexibility without near-term dilution risk (F-HALO-12, F-HALO-13). Sell-side sentiment is uniformly positive (13 buy-equivalent ratings, zero sells, F-HALO-11), and the stock's uptrend is intact and confirmed (price above both 20- and 200-day moving averages, F-HALO-8).
Bear: The stock is technically extended: it closed at its 52-week high with RSI(14) near 70 (F-HALO-8, F-HALO-10) after a 56% three-month return and +52% relative strength versus SPY (F-HALO-9) — a textbook overbought setup that is prone to a mean-reversion pullback, especially heading into the Nov 9 earnings print where expectations are now high. The brief contains no explicit forward P/E, FCF yield, or peer-comparison valuation metrics beyond the EPS guidance implied multiple, so the "cheap growth" framing rests on a single data point. The new $1.5B convertible notes add leverage and introduce dilution risk if shares sustain above the $139.84 conversion price (F-HALO-12, F-HALO-13) — a risk that grows precisely if the bull case plays out and the stock keeps rallying. A new board member (James Daly, F-HALO-14) is a governance detail with no clear near-term fundamental impact and shouldn't be read as a catalyst.
Valuation: On FY2026 non-GAAP EPS guidance of $8.65–9.00 (midpoint $8.825), HALO trades at roughly 13.8x forward earnings at the current $121.51 price — a modest multiple against ~48% revenue growth and 50% royalty growth, suggesting the stock is not expensive relative to its growth and margin trajectory. However, the brief lacks FCF yield, EV/EBITDA, or peer multiples to triangulate this further, and the recent 56% three-month price run has likely compressed some of that apparent discount versus where the multiple stood before the rally. Net: valuation still looks reasonable on an earnings basis, but the margin of safety has narrowed as the stock reached a 52-week high.
undated: Continued ENHANZE/Hypercon deal flow against raised FY2026 guidance
Facts
F-HALO-1: Revenue for the quarter ended June 30, 2026 was $481.0 million, up 47.6% from $325.7 million in the quarter ended June 30, 2025. (as of 2026-08-06)[E5640, E6341]source
F-HALO-2: Royalty revenue for the quarter ended June 30, 2026 was $308 million, up 50% year over year. (as of 2026-08-06)[E6341]source
F-HALO-3: Operating income for the quarter ended June 30, 2026 was $287.7 million, compared with $202.4 million in the year-earlier quarter. (as of 2026-10-15)[E5640]
F-HALO-4: Net income for the quarter ended June 30, 2026 was $229.9 million, compared with $165.2 million in the year-earlier quarter. (as of 2026-10-15)[E5640]
F-HALO-5: On August 6, 2026, Halozyme raised its full-year 2026 guidance to revenue of $1.835–$1.910 billion, royalty revenue of $1.220–$1.245 billion, adjusted EBITDA of $1.225–$1.280 billion, and non-GAAP diluted EPS of $8.65–$9.00. (as of 2026-08-06)[E6341]source
F-HALO-6: Halozyme reported repurchasing 4.8 million shares for $332.8 million at an average price of $69.30 during the second quarter of 2026. (as of 2026-08-06)[E6341]source
F-HALO-7: Halozyme reported signing five ENHANZE and Hypercon collaboration agreements year to date through July 2026, exceeding its stated goal of three for full-year 2026. (as of 2026-08-06)[E6341]source
F-HALO-8: HALO closed at $121.51 on October 15, 2026, equal to its reported 52-week closing high; it was above its 20-day moving average of $112.02 and 200-day moving average of $80.34. (as of 2026-10-15)[E5639]
F-HALO-9: HALO's three-month return through October 15, 2026 was 56.16%, and its three-month relative strength versus SPY was reported as 52.07%. (as of 2026-10-15)[E5639]
F-HALO-10: HALO's RSI(14) was 69.99 on October 15, 2026. (as of 2026-10-15)[E5639]
F-HALO-11: The September 2026 analyst recommendation snapshot listed 3 strong buys, 10 buys, 3 holds, and no sells or strong sells for HALO. (as of 2026-09-01)[E5660]
F-HALO-12: On September 22, 2026, Halozyme completed an offering of $1.5 billion aggregate principal amount of 1.50% convertible senior notes due 2033 and reported net proceeds of approximately $1.471 billion. (as of 2026-09-22)[E6345]source
F-HALO-13: The convertible notes' initial conversion price was approximately $139.84 per share, with an initial conversion rate of 7.1509 shares per $1,000 principal amount. (as of 2026-09-22)[E6346]source
F-HALO-14: Halozyme reported that James Daly was elected to its board on September 28, 2026, with a term ending at the 2029 annual meeting. (as of 2026-09-30)[E6332]source
What would change the view
A close below the 50-day moving average (~$108) on heavy volume, signaling trend breakdown
Q3 2026 results showing royalty revenue growth decelerating meaningfully below the ~50% YoY pace
Guidance cut or withdrawal at the Nov 9 earnings report
Evidence that FY2026 EPS will land below $8.65, pushing the implied forward multiple above ~16x without a growth offset
Data quality
Quality score 96/100.
Gap: The quote block is dated October 16, 2026, one day after the context's stated date of October 15, 2026, and conflicts with the October 15 bar close; the October 15 bar close was used for price and trend facts.
Gap: The fundamentals block is marked fallback and its Finnhub 52-week high and low ($59.45 and $29.89) conflict with the bar data and quote block; those Finnhub range values were not used.
Red flag: The September 2026 convertible notes add $1.5 billion of debt and may create share dilution if converted; the initial conversion price is approximately $139.84 per share.